Hemostemix Inc.

OTCPK:HMTX.F Stock Report

Market Cap: US$7.8m

Hemostemix Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:HMTX.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
31 Oct 24BuyUS$107,984Thomas SmeenkIndividual3,009,491US$0.036
18 Oct 24SellUS$12,991Thomas SmeenkIndividual258,093US$0.054
08 Oct 24SellUS$3,542Thomas SmeenkIndividual74,500US$0.048
07 Oct 24SellUS$76,190Thomas SmeenkIndividual1,480,000US$0.052
21 Aug 24BuyUS$59Thomas SmeenkIndividual2,000US$0.029
25 Jun 24BuyUS$293Thomas SmeenkIndividual10,000US$0.029
01 May 24BuyUS$1,163Thomas SmeenkIndividual40,000US$0.029

Insider Trading Volume

Insider Buying: HMTX.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of HMTX.F?
Owner TypeNumber of SharesOwnership Percentage
Private Companies150,0000.107%
Individual Insiders24,857,29517.7%
General Public115,634,67482.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.4%.

Top Shareholders

Top 5 shareholders own 17.78% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.05%
Ronnie Hershman
11,325,145US$630.5k1,900%no data
4.33%
Peter Lacey
6,096,214US$339.4k0%no data
3.15%
Loran Swanberg
4,426,445US$246.4k9.93%no data
2.14%
Thomas Smeenk
3,009,491US$167.5k66%no data
0.11%
Summerhill Investment Corp
150,000US$8.4k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:06
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hemostemix Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siddharth RajeevFundamental Research Corp.